Earlier diagnosis of multiple sclerosis has long been one of the field's most consequential goals — catching demyelinating disease before irreversible axonal damage accumulates can meaningfully alter a patient's long-term neurological trajectory. The 2024 revision of the McDonald criteria represents a deliberate push in that direction, expanding the diagnostic framework to be both earlier and more inclusive. But as this Nature Medicine perspective argues, the revision simultaneously exposes unresolved scientific gaps that could limit its real-world impact.
The core tension the authors identify is structural: broader diagnostic eligibility increases the risk of misclassification if the underlying biomarkers used to confirm disease are insufficiently specific. The 2024 criteria incorporate evolving fluid and imaging biomarkers — including cerebrospinal fluid markers and refined MRI dissemination-in-time and dissemination-in-space criteria — but the authors contend that the sensitivity-specificity tradeoffs are not yet fully characterized across diverse populations. Disease stratification also remains a challenge; MS is heterogeneous, and a diagnostic label that does not distinguish between radiologically isolated syndrome progressors, relapsing-remitting phenotypes, and primary progressive forms may conflate patients who have meaningfully different prognoses and treatment needs. Clinical trial design must evolve alongside the criteria, since enrolling earlier-diagnosed, biologically broader cohorts affects endpoint selection, follow-up duration, and treatment effect estimation.
This perspective lands at a productive moment in the MS research landscape. Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (GFAP) are increasingly being integrated into monitoring frameworks, and optical coherence tomography offers a window into subclinical neurodegeneration. The authors' call for continued biomarker refinement aligns with a broader consensus that precision neurology — matching treatment intensity to individual biological risk — is the next frontier. The principal limitation here is that this is an expert commentary rather than primary data; its value lies in orienting the research agenda rather than resolving it. Incremental but directionally important.